Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | CTSS | P25774 | 12/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.36 |
| ▸ | ELANE | P08246 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7045911 | 0.82 | EPHX2 (0.47) | HPGDALDH1A1HTTRAB9ACTSS | |
| SCHEMBL7042898 | 0.81 | ALDH1A1 (0.49) | HPGDALDH1A1CTSSCYP3A4CYP2C9 | |
| SCHEMBL7047104 | 0.76 | LMNA (0.45) | HPGDALDH1A1HTTRAB9ACTSS | |
| SCHEMBL6475534 | 0.74 | SMN1; SMN2 (0.39) | ALDH1A1HTTMAPTRAB9ACTSS | |
| SCHEMBL6061692 | 0.73 | CTSS (0.41) | HTTCTSSLMNASMN1; SMN2CYP3A4 | |
| SCHEMBL6467567 | 0.73 | CTSS (0.38) | ALDH1A1HTTMAPTRAB9ACTSS | |
| SCHEMBL7045297 | 0.73 | KDM4E (0.44) | HPGDALDH1A1MAPTLMNASMN1; SMN2 | |
| SCHEMBL7048562 | 0.72 | LMNA (0.48) | ALDH1A1HTTMAPTCTSSLMNA | |
| SCHEMBL6465159 | 0.72 | FAAH (0.44) | ALDH1A1CTSSCYP3A4CYP2C9 | |
| SCHEMBL7049761 | 0.71 | ELANE (0.46) | HTTMAPTLMNASMN1; SMN2ELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030232864-A1 | Novel Compounds and compositions as protease inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2003-12-18 | — | — | US | disclosed |
| US-6576630-B1 | Alkanoyl substituted benzooxazoles or naphthooxazoles | AXYS PHARMACEUTICALS, INC. | 2003-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232864-A1 | Novel Compounds and compositions as protease inhibitors | SERPINB1, CTRL, CTSZ | HPGD 536/4885ALDH1A1 3027/4885HTT 2464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.